TITLE

FDA CLEARS SANGSTAT'S TWO HYMOGLOBULIN IND APPLICATIONS

PUB. DATE
September 2003
SOURCE
Biotech Business;Sep2003, Vol. 16 Issue 9, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports the clearance of two investigational new drug applications of SangStat Medical Corp. by the U.S. Food and Drug Administration in September 2003.
ACCESSION #
10687917

 

Related Articles

  • PHARMA & FINE CHEMICALS: Market Briefs.  // Chemical Market Reporter;02/22/99, Vol. 255 Issue 8, p12 

    Presents news briefs on the market for pharmaceuticals and fine chemicals. Marketing approval received by SangStat in the United Kingdom for the SangCya oral solution or cyclosporine; Approval received by ESI Lederle for its Estradiol Tablets; Centocor's supplemental biologic license...

  • Will hospitals switch to generic cyclosporine? Gebhart, Fred // Drug Topics;12/7/98, Vol. 142 Issue 23, p45 

    Reports on the approval of SangCya, the first generic competitor to Novartis' Neoral (cyclosporine), developed by SangStat Medical Corp. Rating given by the United States Food & Drug Administration on the drug; Amount to be saved annually by the average patient through the drug; Advantages and...

  • ATG PREFERABLE TO OKT3 TO TREAT ACUTE REJECTION.  // Worldwide Biotech;Apr2001, Vol. 13 Issue 4, p3 

    Deals with the recommendation of SangStat company on the use of anti-thymocyte globulin on OKT3 for the treatment of acute rejection episodes.

  • SangStat sells shares, gains $10.2 million.  // Modern Healthcare;1/3/94, Vol. 24 Issue 1, p52 

    Reports on SangStat Medical Corp.'s initial public offering of shares of common stock. Amount raised; Number of shares sold; Company products; Underwriters.

  • Sangstat Will Continue to Offer Cyclosporine Therapy.  // Worldwide Biotech;Sep99, Vol. 11 Issue 9, p1 

    Reports the continued offering of a lower cyclosporine therapy of SangStat, The Transplant Company in Fremont, California, in response to Novartis filing a patent infringement lawsuit against SangStat in the United Kingdom. Claims that Novartis has violated the antitrust laws; United States...

  • Gensia Sicor and Sangsat enter bulk cyclosporin deal.  // Chemical Market Reporter;04/07/97, Vol. 251 Issue 14, p13 

    Reports that an agreement has been reached for Gensia Sicor Inc. to go into commercial production of bulk cyclosporin for SangSat Medical Corp. Uses for cyclosporin; Marketing in different formulations as Sandimmune and Neoral by Novartis Ltd.; Acquisition by Gensia Sicor of Rakepoll Holding BV...

  • Gensia Sicor gets $2.5M investment.  // San Diego Business Journal;01/19/98, Vol. 19 Issue 3, p36 

    Reports on a multimillion investment in Gensia Sicor Incorporated common stock by Menlo Park-based SangStat as part of a licensing agreement. Insight on the companies affiliation;Information on Gensia Sicor.

  • Nationwide Recall: SangCya Oral Solution.  // RN;Sep2000, Vol. 63 Issue 9, p118 

    Informs on the recall of the oral cyclosporine solution SangCya, a generic version of the brand name drug Neoral oral solution used to prevent rejection in kidney, liver and heart transplants. Order of the United States Food and Drud Administration; Manufactured by SangStat Medical Corp.

  • News In Brief. Basu, Paroma; Bouchie, Aaron; Defrancesco, Laura; Depalma, Angelo; Fox, Jeffrey L.; Jia, Hepeng; Louët, Sabine; Norrie., Cheryl // Nature Biotechnology;Sep2003, Vol. 21 Issue 9, p961 

    Presents news briefs related to pharmaceutical industry in the U.S. as of September 2003. Financial performance of Amgen Pharmaceuticals in second quarter of 2003; Acquisition of SangStat Medical Corp. by pharmaceutical company Genzyme Corp.; Information about follow-on offerings in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics